Dr. Brian H. Buck, MD, FRCPC
Claim this profileUniversity of Alberta
Affiliated Hospitals
University Of Alberta Hospital
University Of Alberta
Clinical Trials Brian H. Buck, MD, FRCPC is currently running
Tenecteplase
for Stroke
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. This domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with acute ischemic stroke and are considered for intravenous thrombolysis. In addition, this domain also seeks to study standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) vs. no TNK upfront with rescue IA TNK if necessary (in those eligible for emergency EVT) and no TNK upfront in those who have taken DOACs during the preceding 48 hours. This domain therefore seeks to generate more robust randomized evidence to guide clinicians in their decisions over the balance of risks and treatment with intravenous thrombolysis with tenecteplase wherever such evidence is currently insufficient. This domain will currently evaluate four research questions in relation to the use of IVT with tenecteplase: 1. In patients with recent (48 hours) intake of a standard-dose direct oral anticoagulant (DOAC), how should IVT be used? - Use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg) or not at all. 2. In patients planned to be treated with endovascular thrombectomy, how should tenecteplase be used? -Treat with IV tenecteplase (standard- or low-dose) or not at all. 3. In any patient receiving IVT, what is the optimal dose of tenecteplase? - use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg). 4. To what extent is the treatment effect of standard- vs. low-dose tenecteplase modified by key patient characteristics, such as diabetes, prior antiplatelet therapy, renal failure, or frailty, old age or having a heavy burden of cerebral small vessel disease on brain imaging.
Recruiting
2 awards
Phase 3
Recombinant Factor VIIa
for Hemorrhagic Stroke
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 90 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include those treated within 2 hours with a positive spot sign on a baseline CT angiogram or patients treated within 90 minutes of stroke onset, with or without a positive spot sign.
Recruiting
1 award
Phase 3
2 criteria
More about Brian H. Buck, MD, FRCPC
Clinical Trial Related
2 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Brian H. Buck, MD, FRCPC has experience with
- Tenecteplase
- Aspirin
- Clopidogrel
- Edoxaban 30 Mg
- Edoxaban 60 MG
- Alteplase
Breakdown of trials Brian H. Buck, MD, FRCPC has run
Stroke
Intracerebral Hemorrhage
Atrial Fibrillation
Hemorrhagic Stroke
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian H. Buck, MD, FRCPC specialize in?
Brian H. Buck, MD, FRCPC focuses on Stroke and Intracerebral Hemorrhage. In particular, much of their work with Stroke has involved treating patients, or patients who are undergoing treatment.
Is Brian H. Buck, MD, FRCPC currently recruiting for clinical trials?
Yes, Brian H. Buck, MD, FRCPC is currently recruiting for 2 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that Brian H. Buck, MD, FRCPC has studied deeply?
Yes, Brian H. Buck, MD, FRCPC has studied treatments such as Tenecteplase, Aspirin, Clopidogrel.
What is the best way to schedule an appointment with Brian H. Buck, MD, FRCPC?
Apply for one of the trials that Brian H. Buck, MD, FRCPC is conducting.
What is the office address of Brian H. Buck, MD, FRCPC?
The office of Brian H. Buck, MD, FRCPC is located at: University of Alberta, Edmonton, Alberta T6G2B7 Canada. This is the address for their practice at the University of Alberta.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.